InformationOprozomib (ONX 0912, PR-047) is an orally bioavailable inhibitor for CT-L activity of20S proteasomeβ5/LMP7 withIC50of 36 nM/82 nM. Phase 1/2.In vitroThe anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP, as well as inhibition of migration of MM cells and angiogenesis.In vivoOprozomib is demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response in multiple human tumor xenograft and mouse syngeneic models .Cell Datacell lines：Concentrations：~1 μMIncubation Time：48 hPowder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C25H32N4O7S Molecular Weight: 532.61
- UPC:
- 51202504
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 0.85 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- O408771-1ml
- CAS:
- 935888-69-0
- Product Size:
- 1ml
